Is serum matrix metalloproteinase tissue inhibitor type 1 levels higher in dipper hypertensive patients?
dc.contributor.author | Onrat, E | |
dc.contributor.author | Serteser, M | |
dc.contributor.author | Celik, A | |
dc.contributor.author | Kaya, D | |
dc.contributor.author | Kahraman, A | |
dc.contributor.author | Koken, T | |
dc.contributor.author | Alpaslan, M. | |
dc.date.accessioned | 2020-03-26T16:57:25Z | |
dc.date.available | 2020-03-26T16:57:25Z | |
dc.date.issued | 2005 | |
dc.department | Selçuk Üniversitesi | en_US |
dc.description | 15th European Meeting on Hypertension -- JUN 17-21, 2005 -- Milan, ITALY | en_US |
dc.description.abstract | [Abstract not Available] | en_US |
dc.description.sponsorship | European Soc Hypertens, AstraZeneca, Bristol-Myers Squibb Co, Boehringer Ingelheim, MSD, NOVARTIS, RECORDATI, SANKYO, Sanofi Aventis, Bayer Healthcare AG, Pfizer Inc, Solvay Pharmaceut GmbH | en_US |
dc.identifier.endpage | S253 | en_US |
dc.identifier.issn | 0263-6352 | en_US |
dc.identifier.startpage | S253 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12395/19780 | |
dc.identifier.volume | 23 | en_US |
dc.identifier.wos | WOS:000230639801427 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | en_US |
dc.relation.ispartof | JOURNAL OF HYPERTENSION | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.selcuk | 20240510_oaig | en_US |
dc.title | Is serum matrix metalloproteinase tissue inhibitor type 1 levels higher in dipper hypertensive patients? | en_US |
dc.type | Conference Object | en_US |